Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

PCSA

Live52w low +68.2%

Annual Quarterly

Core line items from PCSA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: Processa Pharmaceuticals, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Annual 2022 2022-12-31
Revenue	Not available	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-8.99M	$-6.82M	$-4.11M	$-27.53M
Net Income	Not available	$-8.72M	$-2.61M	$-4.02M	$-27.42M
EPS (Diluted)	$-1.02	$-6.81	$-5.34	$-3.53	$-34.05
Total Assets	Not available	$8.08M	$10.09M	$12.43M	$8.62M
Total Liabilities	Not available	$914.85K	$930.74K	$2.29M	$1.15M
Cash & Equivalents	Not available	$6.86M	$8.68M	$10.74M	$6.50M
Free Cash Flow OCF − CapEx	Not available	$-5.94M	Not available	Not available	Not available
Shares Outstanding	Not available	24.63M	24.53M	24.53M	801.77K

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from PCSA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +68.2%

Entity: Processa Pharmaceuticals, Inc.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-05	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Annual 2022 2022-12-31
Revenue	Not available	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-8.99M	$-6.82M	$-4.11M	$-27.53M
Net Income	Not available	$-8.72M	$-2.61M	$-4.02M	$-27.42M
EPS (Diluted)	$-1.02	$-6.81	$-5.34	$-3.53	$-34.05
Total Assets	Not available	$8.08M	$10.09M	$12.43M	$8.62M
Total Liabilities	Not available	$914.85K	$930.74K	$2.29M	$1.15M
Cash & Equivalents	Not available	$6.86M	$8.68M	$10.74M	$6.50M
Free Cash Flow OCF − CapEx	Not available	$-5.94M	Not available	Not available	Not available
Shares Outstanding	Not available	24.63M	24.53M	24.53M	801.77K

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.